Neurocrine Biosciences to Participate at Investor Conferences in March

Rhea-AI Summary

Neurocrine Biosciences (NASDAQ: NBIX) will participate in two key investor conferences in Miami this March. The first event is the Barclays Global Healthcare Conference on March 15, 2023, where CEO Kevin Gorman and CFO Matt Abernethy will present at 10:45 a.m. Eastern Time. The second event is the Jefferies Biotech on the Bay Summit on March 16, 2023. Interested parties can access a live webcast of the Barclays presentation via their website, with a replay available for one month after the event.

News Market Reaction – NBIX

-0.84%

-0.84% Session move

In the trading session that priced this news, NBIX declined 0.84%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Barclays Global Healthcare Conference on March 15 in Miami

Jefferies Biotech on the Bay Summit on March 16 in Miami

SAN DIEGO, March 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 10:45 a.m. Eastern Time on Wednesday, March 15 2023 in Miami. Neurocrine Biosciences will participate in the Jefferies Biotech on the Bay Summit on Thursday, March 16 2023 in Miami.

The live presentation at the Barclays Global Healthcare Conference will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-march-301766192.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences participate in the Barclays Global Healthcare Conference?

Neurocrine Biosciences will participate in the Barclays Global Healthcare Conference on March 15, 2023, at 10:45 a.m. Eastern Time.

Who will represent Neurocrine Biosciences at the investor conferences?

CEO Kevin Gorman and CFO Matt Abernethy will represent Neurocrine Biosciences at the investor conferences.

Where are the investor conferences taking place?

Both investor conferences are taking place in Miami.

How can I access the presentation from the Barclays Conference?

The presentation from the Barclays Global Healthcare Conference can be accessed via a live webcast on Neurocrine Biosciences' website.

Is there a replay available for the presentation?

Yes, a replay of the presentation will be available approximately one hour after the event and archived for one month.